trending Market Intelligence /marketintelligence/en/news-insights/trending/IOstm0sEUP426nqxEuJhjA2 content esgSubNav
In This List

Sanofi secures rights to cancer biosimilar for Chinese market

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Sanofi secures rights to cancer biosimilar for Chinese market

Sanofi is partnering with JHL Biotech Inc. to develop and commercialize biological therapeutics for the Chinese market.

Sanofi will invest US$80 million in the Taiwan-based biopharmaceutical company and pay a further US$21 million to secure rights to JHL's proposed biosimilar of Rituximab, a drug used to treat certain types of cancers.

JHL Biotech will be responsible for developing and registering the biosimilar while Sanofi will head commercialization in China.

In addition to sales royalties, JHL Biotech will also be eligible to receive up to US$236 million in milestone payments as a result of the deal.